Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Next Pharmaceuticals has reported positive results of a clinical study conducted at the LaValle Metabolic Institute in Cincinnati, Ohio on Nexrutine, a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion.
Subscribe to our email newsletter
Out of the 401 participants, 369 (92%) reported that Nexrutine provided pain relief and 373 (93%) reported improvement in their overall condition. In total, 361 (90%) reported Nexrutine helped provide a restful sleep.
The study concluded that Nexrutine, when used as a dietary supplement, helps in the management of pain and inflammation and helps promote a restful sleep with minimal side effects. The clinical trial was designed to be an open label, single center, clinical trial and the primary objective of this pilot study was to study the safety and efficacy of Nexrutine.
James LaValle, founder of The LaValle Metabolic Institute and chief investigator of the study, said: “Many of our patients are relieved to find a natural remedy that is not only cardio protective, but unlike aspirin, is easy on the stomach. This study demonstrates that Nexrutine has an excellent safety profile.”